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Background: Metabolic abnormalities are growing concern in 
the treatment of schizophrenia patients. 
Methods: We studied the use of statins among patients enrolled 
in a large scale prospective cohort of 400 clinic based patients. 
During follow-up, nearly 30% of schizophrenic patients treated 
with antipsychotics met criteria for treatment with a statin. The 
effects of statin therapy were evaluated in 46 prospective patients 
with documented dyslipidemia, remaining on the same antipsychotic 
treatment. All patients underwent extensive metabolic screening 
and follow-up, including oral glucose tolerance test. Assessments 
were performed at baseline, 3 months prior to statin therapy and 3 
months after. 
Results: Statin therapy yielded highly significant improvement 
in lipid profile: cholesterol: pre 263.3F62.7; post: 165.3F39.8 
(p=.0001), triglycerides: pre 281.2F272.3; post: 165.7F137.3, 
(p=.0011), LDL: pre 162.2F38.1; post: 87F25.2, (p=.0001), 
non-HDL cholesterol: pre 218.7F67.4; post: 119.0F43.1, 
(p=.0001). However, there were no observed effects on weight, 
waist circumference, fasting glucose, fasting insulin or insulin 
resistance. 
Conclusions: Antipsychotic induced dyslipideaemia can be 
safely and effectively treated with statins. Observed improvements 
in lipid profile are comparable to those seen for general 
populations. 
 
